Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

  • News

Executive Summary

Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals

You may also be interested in...



Ocera Forwards Liver Disease Drug After Reverse Merger With Tranzyme

Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

PS040903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By